Lake Bleu Capital
China's HC Scientific gets $41m Series B extension
Lake Bleu Capital and Guotai Junan Innovation Investment have led a Series B extension of approximately CNY 300m (USD 41m) for HC Scientific, a manufacturer of DNA sequencing devices used in modern agriculture and healthcare.
Carlyle-backed Adicon trades up after $52m Hong Kong IPO
Adicon Holdings, a China-based independent clinical laboratory (ICL) services provider backed by The Carlyle Group, gained 12% on debut following a HKD 408.9m (USD 52.2m) Hong Kong IPO.
Hillhouse-backed China pet services business seeks US listing
New Ruipeng Pet Group, a China-based pet care services platform that counts Hillhouse Capital as a significant shareholder, has filed for an IPO in the US.
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
China's Broncus raises $215m in IPO, struggles on HK debut
Broncus Holding Corporation, a China-based manufacturer of medical devices used to treat lung diseases, plunged 12.8% on its Hong Kong trading debut following a HK$1.67 billion ($215 million) IPO.
Boyu, Janchor back China medical finance start-up
MediTrust Health, China-based healthcare payments and insurance platform, has raised RMB2 billion ($309 million) in Series C funding led by Boyu Capital and Janchor Partners.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
DCP, Sequoia lead Series B for China's Valgen Medtech
DCP Capital has continued its run of investments in China’s medical devices industry by participating in a Series B funding round for Hangzhou Valgen Medtech.
Invesco leads $155m round for China's Brii Biosciences
Invesco has led a $155 million Series C round for China-focused infectious diseases drug developer Brii Biosciences.
Fund focus: LPs flock to Lake Bleu’s late show
Lake Bleu Capital leveraged a lift in Chinese healthcare sentiment to raise $560 million for a fund that will target late-stage healthcare investments
Lake Bleu raises $560m for Asia pre-IPO healthcare fund
Lake Bleu Capital, a Hong Kong-based private equity investor focused on healthcare, has raised $560 million for a pre-IPO fund targeting Asia with an emphasis on Greater China.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.